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ABSTRACT
Objectives: To describe (1) the content of a transition
programme for young people with juvenile idiopathic
arthritis ( JIA) designed as a brief intervention, (2) the
rationale and design of a mixed-methods study
evaluating the clinical impact of this transition
programme and (3) to provide baseline data of the
intervention group.
Design: An ‘embedded experimental’ design is used
for the evaluation of the transition programme. A ‘one-
group pretest-posttest, with a non-equivalent posttest-
only comparison group design’ is used to quantitatively
evaluate the impact of the transition programme,
applying both longitudinal and comparative analyses.
Subsequently, experiences of adolescents and their
parents who participated in the experimental group will
be analysed qualitatively using content analysis.
Setting: Participants in the intervention are recruited at
a tertiary care centre in Belgium. The comparison
group participants are recruited from one tertiary and
three secondary care centres in Belgium.
Participants: The intervention group consists of
33 young people (25 females; 8 males) with a median
age of 16 years. Main diagnoses are persistent or
extended oligoarticular JIA (33%), polyarticular JIA
(30%), enthesitis-related JIA (21%) or systemic
arthritis (15%).
Intervention: The transition programme comprises
eight key components: (1) transition coordinator;
(2) providing information and education; (3) availability
by telephone; (4) information about and contact with
an adult care programme; (5) guidance of parents;
(6) meeting with peers; (7) transfer plan; and (8) actual
transfer to adult care.
Primary and secondary outcomes: The primary
outcome is health status, as perceived by the
adolescents. Secondary outcomes are health status,
as perceived by the parents; medication adherence;
illness-related knowledge; quality of life; fatigue;
promotion of independence; support of autonomy;
behavioural control and psychological control.
Results: At baseline, the median score was 69.2
(Q1=60.0;Q3=92.9) on psychosocial health and 68.8
(Q1=56.3; Q3=89.1) on physical health. Rheumatic-
specific health scores ranged from 62.5 to 100.
Conclusions: We present the rationale and design of a
study intended to evaluate a transition programme for
adolescents with JIA as a brief intervention.
BACKGROUND
Some decades ago, several paediatric disor-
ders were associated with high, progressive
morbidity and increased mortality. For many
people suffering from these chronic diseases,
medical, surgical and technological advance-
ments have resulted in improved disease
management and increased life expectancy.
Unlike in the past decades, children with a
progressive deteriorating disorder now often
live into adulthood managing a chronic
disease. Expert lifetime care should be
Strengths and limitations of this study
▪ A transition programme for adolescents with
juvenile idiopathic arthritis is developed as a
brief intervention, which may be less costly and
time-consuming than the existing, more compre-
hensive transitional care interventions.
▪ The development and evaluation of this transition
programme is guided by the initial Medical
Research Council framework for complex
interventions.
▪ The use of a sequential mixed methods approach
within the framework for complex intervention
enables a full and integrative insight into the clin-
ical impact of the key components of the transi-
tion programme.
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provided for these patients in order to maximise their
potential and lifelong functioning.
Young people with chronic conditions undergo differ-
ent stages during their life. Two of the many important
phenomena that occur include a developmental transi-
tion into adulthood, a phase during which young people
evolve from being a dependent child to becoming an
independent adult.1 Second, their setting of care is
transferring from a paediatric context to an adult-
focused environment. Indeed, a timely and well-
prepared transfer to adult-centred care is advocated.2 3
This transfer is defined as an event or series of events
through which adolescents and young adults with
chronic physical and medical conditions move their care
from a paediatric to an adult healthcare environment.4
According to the recent literature, the paediatric-to-
adult transfer of care should be preceded by a prepara-
tory transitional phase. Transition is therefore defined as
a process by which adolescents and young adults with
chronic childhood illnesses are prepared to take charge
of their lives and their health in adulthood.4
In order to prepare young people to take on new
responsibilities for their health and to anticipate the immi-
nent transfer to adult care, transition programmes have
been developed. The efficacy of these transition pro-
grammes has been evaluated to some extent in the last
decade.5–11 Using quasi-experimental designs, investiga-
tors have found some positive effects on the quality of
life,8 disease outcomes,5 7 number of admissions and the
length of stay of readmissions,7 knowledge,8 work experi-
ence and career advice8 and satisfaction with care.10 The
vast majority of the studies have been conducted in the
UK,12 which may limit the generalisability of the study
findings to other healthcare systems due to, for example,
differences in financing and reimbursement of healthcare
expenditures. Therefore, research on the efficacy of transi-
tion programmes in other countries is warranted.12
Existing transition programmes generally adopt a com-
prehensive approach that is very likely contributing to
their positive effects. However, such extensive pro-
grammes are also perceived as being costly and time-
consuming to implement in day-to-day practice,
although economic cost-effectiveness studies are cur-
rently lacking. This is illustrated by the finding that the
most frequently reported barriers to the formal transi-
tion of patients are limited time and lack of funding for
a transition coordinator.13 14 Hence, the cost-
effectiveness of transition programmes can be ques-
tioned. In times of economic crisis and limited funding,
more sustainable alternatives must be explored. Brief
evidence-based interventions have the potential to be
cost-effective and therefore are more likely to be imple-
mented in clinical practice.
Transition programmes can be viewed as complex
interventions. Complex interventions are built up from a
number of components that may act independently and
interdependently.15 This implies that the active ingredi-
ent of the intervention is unknown or difficult to specify.
The British Medical Research Council (MRC) has pro-
vided a framework for developing and evaluating
complex interventions. It entails a recursive process of
development, feasibility and pilot testing, evaluation and
implementation of the complex intervention. Hence,
before any formal efficacy assessment can be performed,
comprehensive preparatory work is conducted.15
The original model of the MRC comprised an investi-
gative sequence of five phases (figure 1). First, theory
and evidence are assessed in order to provisionally iden-
tify the steps and the key components of the interven-
tion; this is termed the preclinical phase. Second, an
understanding of the intervention and its possible
effects is developed; this is termed phase I: the model-
ling phase. Third, the feasibility of key components is
assessed, and the recruitment procedures and measure-
ments of outcomes are tested; this is termed phase II:
the exploratory trial phase. Fourth, randomised con-
trolled trials are conducted to evaluate the impact of the
complex intervention. These trials require adequate
power, adequate randomisation, appropriate outcome
measures and other standard features of well-designed
trials; this is termed phase III: the definitive randomised
controlled trial. Finally, separate studies are conducted
to establish the long-term and real-life effectiveness of
the intervention; this is termed phase IV: the long-term
implementation.15 16
In order to develop and test a transition programme
involving a complex and brief intervention, we established
the DON’T RETARD project (Devices for the
OptimisatioN of TRansfEr and Transition of Adolescents
with Rheumatic Disorders). This project was designed for
young people with juvenile idiopathic arthritis (JIA)
(http://www.kuleuven.be/switch2/rheuma.html) and
aimed to provide a proof of concept for a transition pro-
gramme devised as a brief intervention. We followed the
original MRC framework for complex interventions. As
part of the modelling phase, we conducted some prepara-
tory studies that were previously published elsewhere.14 17
The next step in the DON’T RETARD project is to evalu-
ate the newly developed transition programme.
In the present article, we aim (1) to extensively
describe the content of a transition programme for
young people with JIA that was designed as a brief inter-
vention, (2) to describe the rationale and design of a
mixed methods study evaluating the clinical impact of
this transition programme and (3) to report the baseline
characteristics of the intervention group on the respect-
ive primary and secondary outcomes. We hypothesise
that the transition programme would improve the phys-
ical, psychosocial and rheumatic-specific health of ado-
lescents with JIA (primary outcome).8 18 Second, we
hypothesise that the programme would improve medica-
tion adherence, illness-related knowledge, quality of life,
threshold to fatigue and parenting styles in patients who
participate in the programme (secondary outcomes). To
guarantee the transparency and quality of describing
this complex intervention, we used the recently
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published criteria for reporting the development and
evaluation of complex interventions (CReDECI).19 The
results on the clinical impact of the transition pro-
gramme will be reported in a forthcoming publication.
Transition programme as a brief intervention
Our transition programme, which is designed to be a
brief intervention, contains five steps. We will describe
each step in the next section.
Intervention steps
1. The first step occurs during a scheduled outpatient
visit. The paediatric rheumatologist introduces the
transition coordinator (TC) to the patient (aged 14–
16 years) and his or her parents, and explains the
transition programme. During this first face-to-face
visit with the TC, the TC provides the patient and
parents with a rheumatology management diary (ie,
a booklet including self-reporting symptoms scales,
an overview of scheduled appointments, space for
writing down questions, etc), written information
about JIA and medication management and a DVD
with instructions regarding appropriate exercising.
The TC guides the young person and parent(s)
through three patient information websites and pre-
sents a video about JIA and its consequences. Young
people have the possibility to see the rheumatologist
and TC without the presence of their parent(s). This
independent visit is strongly encouraged.
Furthermore, a second face-to-face visit with TC is
scheduled. The initial contact session lasts about 30–
40 min. The TC is, however, continuously available by
telephone to answer additional questions about the
condition, therapy, transition process, health behav-
iour and clinic appointments.
2. The second step of the intervention occurs 6 months
later, and consists of a second face-to-face visit with
TC, taking place at the paediatric outpatient clinic.
During this visit, TC discusses health behaviour and
deals with fatigue, school, friends, self-image, knowl-
edge about the disease and any difficulties with medi-
cation adherence. Participants receive a folder about
the practical issues related to the adult rheumatology
programme (eg, contact information for the secre-
tary and rheumatologists, organisational information
for the outpatient clinic). This session lasts approxi-
mately 30 min.
3. For the third step of the intervention, patients and
their parents are invited to attend an adolescent
information day. On this day, all patients who
attended their second visit with the TC are invited to
come together. The adolescent information day has
two parallel programmes: one for the adolescents
and one for the parents. The programme for adoles-
cents begins with a brief introduction from the TC
and the paediatric rheumatologist. Then the adoles-
cents take part in a variety of activities: they meet
with peers, take an orientation tour at the adult care
facilities, meet with the rheumatologists, physiother-
apist(s) and nurse specialist of the adult rheumatol-
ogy team, and attend a workshop on psychological
issues. These activities are followed by a cooking
workshop, in which the adolescents prepare a com-
plete meal for themselves and their parents. This
allows them to talk with their peers in an informal
setting.
Figure 1 Development of a
complex intervention based on
the Medical Research Council
framework and its evaluation
using an embedded experimental
design.
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4. The parallel programme for parents during this third
step of the intervention is similar. A parent association
representative is available so that the parents can
express their concerns about their child’s transition to
adulthood. Activities include taking an orientation
tour at the adult care facilities, meeting with the rheu-
matologists and nurse specialist of the adult rheuma-
tology team, and attending a lecture on psychological
issues inherent to the development of an adolescent
with chronic disorders. After the formal programme,
parents join their children for the dinner prepared by
the children. The adolescent information day starts at
14:00 and ends at 18:30, and takes place twice during
the transition programme. For each information day,
about 15 patient-parents dyads participate.
5. For the fourth step, an individualised transfer plan is
developed by the TC based on conversations with the
young person and the parents. This plan is developed
before transferring the patient from paediatric to
adult rheumatology. This plan is based on the coding
structure of the International Classification of
Functioning, Disability and Health for Children and
Youth (ICF-CY). By shifting the focus from cause to
impact, the ICF-CY puts all health conditions on an
equal footing, allowing them to be compared using a
common metric. Furthermore, it takes into account
the social aspects of a disability and does not view dis-
ability only as a ‘medical’ or ‘biological’ dysfunction.
By including contextual factors, in which environ-
mental factors are listed, the ICF-CY allows us to
record the impact of an environment on a person’s
functioning. The transfer plan is also based on
patient information collected by the paediatric
rheumatologist, the TC and other healthcare profes-
sionals that are consulted. The development of a
transfer plan requires 30 min/patient.
6. The fifth step is the actual transfer. Once the transfer
plan is handed over to the adult rheumatologist, the
patient is considered transferred to an adult rheuma-
tology care. The third face-to-face visit with the TC
occurs during the patient’s first outpatient visit to the
adult rheumatology care. This time, the rheumatolo-
gist of the adult rheumatology programme joins the
session, along with the TC, patient and parents. The
TC focuses on health behaviour and medication
information. During this outpatient visit, the patient
is formally ‘handed over’ to the adult rheumatology
providers. This session lasts about 20 min.
Intervention key components
The transition programme comprises eight key compo-
nents that are implemented in one or more of the five
steps: (1) a transition coordinator; (2) providing infor-
mation and education about JIA and medication man-
agement, health behaviour, dealing with fatigue, school,
friends and any problems with medication adherence;
(3) availability by telephone; (4) information about
and contact with the adult rheumatology programme;
(5) guidance of parents; (6) meeting with peers; (7) a
transfer plan and (8) the actual transfer to the adult
rheumatology programme.
Altogether, TC spends 60–90 min/patient, spread over
a period of 1.5 years. This is in addition to the 40 man-
hours (for the TC, paediatric rheumatologists, rheuma-
tologists of the adult setting, physiotherapists, nurses of
adult rheumatology, psychologists) incurred by the ado-
lescent information day activities and the 20 h needed
for its preparation. Overall, it was estimated that the
time and work investment of one full-time equivalent is
needed to implement this brief intervention for a case-
load of 250–300 transitioning patients.
METHODS AND DESIGN
To develop and evaluate the transition programme, we
apply a mixed methods approach in which quantitative
and qualitative studies are combined. More specifically,
we use an ‘embedded experimental design’.20 This
design is characterised by a set of qualitative studies that
are conducted before and after a quantitative study. In
our project, the embedded experimental design starts
with a qualitative study using in-depth interviews. The
aim of these interviews is to better understand the transi-
tional needs of young people with JIA. The information
obtained in this qualitative study assisted us in develop-
ing the transition programme. Hence, this particular
qualitative study corresponds to the modelling phase of
the MRC framework (figure 1, green box). The
methods and results of this first qualitative study are
reported in two related articles.21 22 Therefore, we do
not elaborate on this study in the present article.
However, we did not rely solely on our qualitative find-
ings to determine the content of the transition pro-
gramme. Indeed, we built on previously published
studies on transitional care.8 10 21–23
Subsequently, we conduct a quasi-experimental study
employing a ‘one-group pretest-posttest, with a
non-equivalent posttest-only comparison group’ design
(figure 1, purple box; figure 2). In this quantitative
study, we investigate the clinical outcomes of patients
with JIA and their parents who participate in the transi-
tion programme. In this respect, longitudinal analyses
will be conducted to investigate changes over time
(figures 1 and 2; indicated in red). Furthermore, com-
parative analyses will be performed by comparing the
post-test scores of the intervention group with those of
the patients who received usual care (figures 1 and 2;
indicated in blue). This quantitative study is called
study 1 in figure 2. After this initial quantitative study, a
second-qualitative study using an explanatory design is
conducted (study 2; indicated in orange), in which we
elaborate on the experiences of adolescents with JIA
and their parents regarding their participation in the
transition programme. Both studies 1 and 2 are consid-
ered to correspond to the exploratory trial phase of the
MRC framework (see Background section).
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Study 1.a. Quantitative study: longitudinal analysis
Inclusion criteria
Potential participants are recruited during a scheduled
visit at the outpatient clinic, between 1 February 2009
and 1 February 2011. Dutch-speaking young people
(14–16 years of age) with JIA, treated and in active
follow-up at the Department of Paediatric Rheumatology
of the University Hospitals Leuven, are invited to partici-
pate in the intervention trial. Patients are excluded if
they have developmental or cognitive disabilities or if
they do not have the physical capacity to complete the
questionnaires used in the study. The convenience
sample includes all eligible participants.
Informed consent
Patients are included after obtaining written informed
consent from the parents and informed assent from the
patients (all patients were minors at the time of inclu-
sion). Anonymity is guaranteed, and patients and
parents are assured that they could stop participating at
any time.
Variables and measurements
All participants are assessed three times: at baseline
(T0), at the second outpatient visit at paediatric rheuma-
tology (T1), and at the first outpatient rheumatology
consultation in the adult care setting (T2; figure 2). At
each point in time, we measure the primary and second-
ary outcomes as well as the disease parameters. The
primary outcome of interest is the self-perceived health
status of the patient, as measured with the Pediatric
Quality of Life Inventory (PedsQLTM). We use the
generic (PedsQL 4.0 Generic Core Scales) and the
disease-specific module (PedsQL 3.0 Rheumatology
Module).24–26
We measure the following set of secondary outcomes
salient to the young people: the patients’ health status as
perceived by their parents, which is measured with the
PedsQL 4.0 Generic Core Scales and PedsQL 3.0
Rheumatology Module.24–26 Furthermore, a set of
patients’ self-reported secondary outcomes are assessed:
medication adherence is measured using a Visual
Analogue Scale (VAS) and the Swiss HIV Cohort Study
Adherence Questionnaire (SHCS-AQ)27; illness-related
knowledge is measured using the modified Patient
Knowledge Questionnaire (PKQ)28; and the level of
global quality of life is measured using a Linear Analogue
Scale (LAS).29 Fatigue is measured using the
Multidimensional Fatigue Inventory (MFI-20).30 Finally,
in the group of parents, four dimensions of parenting are
assessed using parent-reported instruments. Promotion
of independence by parents is measured using the
Promotion of Independence Scale31 and support of
autonomy is measured using the Autonomy Support
Scale.32 Furthermore, the level of behavioural control (ie,
parental monitoring of child’s behaviour) is assessed
using the Parental Regulation Scale,33 while the aspect of
psychological control (ie, intrusive and manipulative
form of controlling) is measured using the Psychological
Control Scale.33 These outcomes are all found to be sub-
optimal in patients with JIA.23 31 33–35 We hypothesise
that participation in the transition programme could
improve medication adherence, illness-related knowl-
edge, quality of life, fatigue and parenting style.
Figure 2 Flow chart illustrating
the quantitative and qualitative
studies used to assess the
transition programme for
adolescents with juvenile
idiopathic arthritis. In study 1,
quantitative analyses were
conducted based on a one-group
pretest–post-test design with a
non-equivalent posttest-only
comparison group composed of
adolescent–parent dyads. This
was followed by study 2,
a qualitative study consisting of
in-depth interviews.
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With regard to the disease parameters, we evaluate the
clinical status of the disease activity and clinical remis-
sion on/off medication according to the preliminary cri-
teria of Wallace et al.36 Furthermore, the functional
status is assessed by the patient-reported and
parent-reported Child Health Assessment Questionnaire
(CHAQ-DI).37–39 Detailed information about the instru-
ments used to assess the clinical impact of the transition
programme are shown in table 1.
Data analysis
Since this study is an exploratory trial formulated
according to the MRC framework of complex interven-
tions, our aim is not to test the efficacy of the transition
programme; rather, it is a ‘proof of concept’ for the tran-
sition programme as a brief intervention. Therefore, we
will not look for statistical significances but rather for
clinical differences. Differences in patient-related and
parent-related outcomes, which are measured continu-
ously starting at T0 (before intervention) to T2 (after
intervention), will be expressed as effect sizes.
For continuous variables, an effect size for the
Wilcoxon test will be calculated by using r= Z/νn, where
Z is the normal approximation of the Wilcoxon test stat-
istic. To appraise the magnitude of the effect sizes, we
will use Cohen’s r. An effect size of 0.1–0.3 is considered
to be small, whereas effect sizes of 0.3–0.5 and ≥0.5 are
considered to be medium and large, respectively.40
Adherence will be dichotomised as adherent or non-
adherent. For this outcome, ORs will be calculated to
report the effect size. The OR is the ratio of the odds of
an outcome (eg, being adherent) of one group (T0,
before intervention) to the odds of the outcome of the
other group (T2, after intervention). To appraise the
magnitude of this OR, we will use the following sug-
gested cut-off values: 1.5–2.5 is a small effect; 2.5–4.3 is a
medium effect; and 4.3 or higher is a large effect.41 42
Nominal data will be expressed in frequencies and
percentages. Medians and quartiles (Q1–Q3) will be cal-
culated for continuous, non-normally distributed
variables.
Baseline data
The intervention group consists of 33 young people, 25
of whom are female and 8 male. Detailed information
about JIA subtype, prescribed medication and remission
status (on or off therapy) and the outcome data is
shown in table 2. At baseline, patients reported a
median score on psychosocial health of 69.2 (Q1=60.0;
Q3=92.9) and 68.8 (Q1=56.3; Q3=89.1) on physical
health (PedsQoL). For rheumatic-specific health
(PedsQoL), median scores ranged between 62.5 and
100, with the worst scores for pain and hurt and the best
scores for daily activities (PedsQoL). Furthermore,
patients reported a median score for functional status
(CHAQ-DI) of 0.3 (Q1=0.1; Q3=0.6) and 73.0 (68.5;
90.0) on the quality of life (LAS). Regarding fatigue, the
scores on the motivation subscale were worst (7.0).
Ethical issues
The Institutional Review Board of the University
Hospitals Leuven, Belgium evaluated and approved the
study protocol (B32220096363). This study is performed
with ethical standards as described in the latest
Declaration of Helsinki.
Study 1.b: Quantitative study: comparative analysis
Inclusion criteria
The intervention group’s participant inclusion criteria
are described above. The comparison group consist of
45 young people aged 17–23 years and their parents.
These patients already have been transferred to the
adult rheumatology programme without participating in
a specific self-management/transition programme (ie,
they received the usual care). The comparison group
participants were recruited from four different health
centres in Belgium. Patients who have developmental or
cognitive disabilities or do not have the physical capacity
to complete the questionnaires are excluded.
Participants of the comparison group (n=23) are
included in the analyses if they can be matched with an
intervention group participant in terms of disease activ-
ity, medication prescribed, JIA subtype and gender.
Definition of usual care
For the purposes of this study, usual care is defined as
the care that is currently provided in day-to-day clinical
practice. Young people with JIA are usually followed up
at the paediatric rheumatology programme until the age
of 16 years. Around that age, the adolescent might have
a first outpatient visit with the adult rheumatologist and
the paediatric rheumatologist together. When the rheu-
matologists, the patient and his or her parents agree
that the patient is ready for transfer, an appointment for
an adult rheumatology consultation is made. No TC or a
formal transition plan is provided to patients who
receive the usual care.
Informed consent from the comparison group subjects
We use the same procedure described above that we use
for the intervention group; the young people above
18 years of age provide their own written informed
consent.
Variables and measurements
The variables and measurements used in these compara-
tive analyses are the same as those used in the longitu-
dinal analyses (see above). The measures for the
comparison group are acquired during one of the
scheduled outpatient visits at the adult care clinic (T2;
see figure 2).
Data analysis
As with the longitudinal analyses, we are interested in
clinical differences instead of statistical differences. In
the comparative analyses, the scores of the intervention
and comparison groups at T2 will be compared. The
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Table 1 Overview of variables and measurements in the quantitative study
Variable Measurement Report Items Validity Reliability Responsiveness Interpretation
Perceived health
status
Paediatric Quality of Life
Inventory (PedsQL 4.0)
Generic Core Scale
PAT &
PAR
23 Construct validity
confirmed,
ref. 24, p.333–335;
ref. 25, p.809;
ref. 26, p.719
Internal consistency confirmed
Adolescents’ self-report:
Total score, α=0.91–0.92;
physical health, α=0.83–0.90;
psychosocial health,
α=0.87–0.89
Parents’ proxy report
Total score, α=0.92–0.94;
physical health, α=0.88;
psychosocial health, α=0.89–
0.91,24 p.335;, 26 p.718
Responsiveness
confirmed,26
p.721–722
Scores from 0 to 100
Higher scores indicate a
better perceived health
status
Paediatric Quality of Life
Inventory (PedsQL 3.0)
Rheumatology Module
PAT &
PAR
22 Construct validity
confirmed,26
p. 720–721
Internal consistency confirmed
Adolescents’ self-report
pain and hurt, α=0.90; daily
activities, α=0.84; treatment,
α=0.77; worry, α=0.81;
communication, α=0.79
Parents’ proxy report :
Pain and hurt, α=0.90; daily
activities, α=0.89; treatment,
α=0.77; worry, α=0.80;
communication,
α=0.91,26 p. 718
Responsiveness
confirmed
Scores from 0 to 100
Higher scores indicate a
better perceived
rheumatological health
status
Medication
adherence
Visual Analogue Scale
(VAS)
PAT 1 NR NR NR Scores from 0 to 100
Higher scores indicate
better medication
adherence
SWISS HIV Cohort
Study Adherence
Questionnaire
SHCS-AQ 27
PAT 2 NR NR NR medication adherent or
non-adherent
Illness-related
knowledge
The Modified Patient
Knowledge
Questionnaire (PKQ)
PAT 16 Content validity
confirmed28
NR NR Scores from 0 to 100
Higher scores indicate
more illness-related
knowledge
Global quality of life Linear Analogue Scale
(LAS)
PAT 1 Content validity
confirmed;
construct validity
confirmed,29 p.410
stability confirmed (ICC=0.65;
p<0.001),29 p.410
Responsiveness
confirmed,29 p.410
Scores from 0 (worst
imaginable quality of life)
to 100 (best imaginable
quality of life)
Fatigue Multidimensional
Fatigue Inventory
(MFI-20)
PAT 20 Construct validity
confirmed,30 p. 6
Internal consistency confirmed:
General fatigue, α=0.82;
physical fatigue, α=0.81;
Responsiveness
confirmed,30 p.6
Scores from 4 to 20
Higher scores indicate a
higher degree of fatigue
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Table 1 Continued
Variable Measurement Report Items Validity Reliability Responsiveness Interpretation
reduced activity, α=0.82;
reduced motivation, α=0.71;
mental fatigue, α=0.86,30 p.4–6
Parenting
dimensions
A. promotion of
independence
B. support of
autonomy
C. behavioural
control
D. psychological
control
Promotion
Independence Scale
(PI)
Autonomy Support
Scale (PVF)
Parental Regulation
Scale (PRS-YSR
revised to parent
self-report)
Psychological Control
Scale (PCS-YSR
revised to parent
self-report)
PAR
8
7
16
8
NR
NR
Construct validity
confirmed33 p. 309
NR
Internal consistency confirmed
(α=.76),31 p.17
Internal consistency confirmed
(α=0.70–0.72),32 p.1420
NR
Internal consistency confirmed
(α=0.69),33 p.545–546
NR
NR
NR
NR
Scores from 1 to 5
a. higher scores indicate
more promotion of
independence
b. higher scores indicate
more support of
autonomy
c. higher scores indicate
more behavioural control
d. Higher scores indicate
more psychological
control
Absence of disease
activity
36 MD NA NA NA NA Inactive disease or active
disease
Two types of
clinical remission:
a. Clinical
remission on
medication
b. Clinical
remission off
medication
36 MD NA NA NA NA No clinical remission,
clinical remission on
medication, or
clinical remission off
medication
Functional status Childhood Health
Assessment
Questionnaire
(CHAQ-DI)37 38
PAT &
PAR
30 Construct validity
confirmed39 p. 980
NR NR Scores from 0 (good
functional status) to 3
(poor functional status)
ICC, intra-class correlation; MD, medical doctor; NA, not applicable; NR, not reported; PAT, patient; PAR, parent.
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Table 2 Demographic, clinical characteristics and baseline outcome data of young people with JIA included in the
intervention group (n=33)
Baseline data
Sex n (%)
Female 25 (75.8)
Male 8 (24.2)
Subtype of JIA based on preliminary criteria of Wallace36 n (%)
Persistent/extended oligoarticular JIA 11 (33.3)
Polyarticular JIA (RF-, RF+) 10 (30.3)
Systemic arthritis 5 (15.1)
Enthesitis-related arthritis 7 (21.2)
Age median, in years (Q1;Q3) 16 (15.2;17.1)
Presence of JIA disease activity n(%) 10 (30.3)
Functional status (CHAQ-DI patient report) median (Q1;Q3) 0.3 (0.1;0.6)
Presence of clinical remission on therapy n (%) 17 (51.5)
Presence of clinical remission off therapy n (%) 5 (15.2)
Prescribed medication n (%) 23 (69.7)
NSAIDS 14 (60.9)
DMARDS 10 (43.5)
Biologicals 6 (26.0)
Glucocorticoids 4 (17.4)
Primary outcomes in young people median (Q1;Q3)
Perceived health status (PedsQL 4.0 Generic Core Scale)
Psychosocial health 69.2 (60.0;92.9)
Physical health 68.8 (56.3;89.1)
Perceived health status (PedsQL 3.0 Rheumatology Module)
Treatment 76.8 (71.4;100)
Communication 75.0 (66.7;91.7)
Pain and hurt 62.5 (50;93.8)
Daily activities 100.0 (91.3;100.0)
Worry 75.0 (66.7;91.7)
Secondary outcomes in young people median (Q1;Q3)
Global quality of life (LAS) 73.0 (68.5;90.0)
Illness-related knowledge (PKQ) 31.3 (18.8;43.8)
Fatigue (MFI-20) median (Q1;Q3)
Motivation 7.0 (5.3;9.0)
Mental fatigue 9.5 (7.0;12.8)
Activity 9.5 (7.0;12.0)
Physical fatigue 9.5 (6.3;13.8)
General fatigue 9.5 (7.3;13.0)
Presence of medication adherence (SHCS-AQ) 23 (69.7%)
Secondary outcomes in parents median (Q1;Q3)
Dimensions of parenting style median (Q1;Q3)
Autonomy support (PVF) 3.8 (3.3;4.3)
Promotion of independence (PI) 3.4 (3.1;1.8)
Behavioural control (PRS-YSR revised to parent self-report) 4.0 (3.6 : 4.3)
Psychological control (PCS-YSR revised to parent self-report) 2.0 (1.8;2.5)
Perceived health status (PedsQL 4.0 Generic Core Scale, parent report)
Psychosocial health 85.0 (71.7;90.0)
Physical health 73.0 (56.3;96.9)
Perceived health status (PedsQL 3.0 Rheumatology Module, parent report)
Treatment 89.3 (71.4;97.3)
Communication 75.0 (64.6;91.7)
Pain and hurt 84.4 (50.0;95.3)
Daily activities 100.0 (90.0;100.0)
Worry 91.7 (66.7;100.0)
DMARDs, disease modifying antirheumatic drugs; JIA, juvenile idiopathic arthritis; NSAIDs, non-steroidal anti-inflammatory drugs.
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cut-off values used for the longitudinal analyses will also
be used for the comparative analyses.
Ethical issues
The Institutional Review Board of the University
Hospitals Leuven, Belgium, evaluated and approved the
study protocol (B32220096363). This study is performed
with ethical standards as described in the latest
Declaration of Helsinki.
Study 2: Qualitative study
Design
We use an explanatory design to expand the quantitative
results with the qualitative data.20 To gain insight into
the processes underpinning the transition programme,
we conduct in-depth interviews with the young people
and parents of the intervention group. The specific aims
of this qualitative study are (1) to get an understanding
of the reasons why particular effects are observed, and
(2) to evaluate the feasibility and utility of the key com-
ponents of the complex intervention from the patients’
and parents’ perspectives.
Inclusion criteria
Those participating in the intervention group of this
qualitative study (young people and their parents) are
purposively sampled and invited to take part in the inter-
views. Sampling continues until no new themes emerge
from the data (ie, until data saturation is reached).
Informed consent
Participants are included in the qualitative study after we
obtain written informed consent for this particular
study. If the patient is a minor, informed consent is
obtained from the parents and informed assent from
the patient. Anonymity is guaranteed, and patients and
parents are assured that they can stop the interview at
any time.
Data collection
We employ a predefined interview guide, previously
adjusted by an expert panel consisting of one rheuma-
tologist (RW), one paediatric rheumatologist (CW) and
three researchers (KV, PM and DH) in the field of care
transition. We ask young people and parents to answer
open-ended questions about TC, the adolescent infor-
mation day, the time of transfer and general experiences
about the transition programme intervention.
Young people and parents are interviewed at home,
each in a different room. Different strategies are used to
assess the trustworthiness of the research: investigator tri-
angulation, bracketing and building a relationship of
trust with the participant. Investigator triangulation
requires that more than one investigator collect and
analyse the raw data, so that the findings emerge
through a consensus of a team of investigators.43
Bracketing is the process of identifying and holding in
abeyance preconceived beliefs and opinions about the
phenomenon under study.43 Bracketing makes the
researcher aware of his or her beliefs and opinions
about the phenomenon under study. To build a trusting
relationship with each participant, we make certain that
the interviewers are not part of the therapeutic team
and that the interviews take place in a room where the
participant feels comfortable. These methods ensure
that researcher-related bias is minimised.
Data analysis
The interviews will be analysed by using the qualitative
content analysis, according to the method of Graneheim
and Lundman.44 Each interview is audiotaped and tran-
scribed verbatim. The interviews will be read through
several times to obtain a good understanding of the
content. The first step in the analysis is the identification
of meaning units (ie, constellations of words or state-
ments that are related to the same central meaning).
The meaning units are labelled with codes, which allow
the data to be considered in new and different ways.
The second step in the analysis involves sorting the
codes into themes. A theme is an expression of the
latent content of the text. For each theme, its content is
expressed in two categories. To ensure the trustworthi-
ness of the analysis, the authors discuss the classification
of codes, categories and themes until consensus is
reached.
Ethical issues
The Institutional Review Board of the University
Hospitals Leuven, Belgium, evaluated and approved the
study protocol. This study is performed with ethical stan-
dards as described in the latest Declaration of Helsinki.
Discussion
Previous studies have shown that the implementation of
a comprehensive transition programme can have positive
effects on several patient outcomes. We developed a
transition programme for young people with JIA as a
brief intervention. Implementation of these transition
programmes in clinical practice may be more feasible,
because we estimated that one full-time equivalent of
manpower of the entire team could take on a case load
of 250–300 transitioning patients in this transition pro-
gramme. In the present article, we describe the rationale
and the design of a mixed methods approach for evalu-
ating the clinical impact of the transition programme
for young people with JIA, and provide baseline data.
Our study is innovative in four aspects. First, to the
best of our knowledge, this is the first evaluation of a
transition programme structured as a brief intervention.
Brief interventions are usually conducted in a
one-on-one situation and take shorter periods of time.45
Brief interventions are predominantly used in the pre-
vention and treatment of substance abuse,46 although
they have been employed in other settings as well.47 48
Shorter time-consuming interventions are in demand,
since the current trend is to implement transition
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programmes through optimal time use and cost-efficacy.
However, as pointed out by McDonagh et al49, training
of healthcare professionals will require additional
resources.
Second, we designed this brief intervention as a
complex intervention and used the MRC framework to
perform our evaluation. It is argued that even simple
interventions can be complex undertakings, mixing ele-
ments of content, intensity, duration and setting.45
Therefore, clearly specifying the steps and components
of a brief intervention is needed. For this purpose, we
used the criteria for the development and evaluation of
complex interventions (CReDECI) in healthcare.19
Third, within this complex intervention framework, we
employ a sequential mixed methods approach, more
specifically an embedded experimental design. This
mixed methods approach enables us to gain better
insight into the clinical impact of the key components of
this complex intervention. Using this approach, we inte-
grate the findings of our different studies.
Mixed methods studies differ from multimethods
studies in that the latter involve a set of monomethod
studies that use different designs and that are conducted
independently. Although integration is highly advocated,
it is seldom conducted. The reason can be explained in
two ways.50 First, researchers do not always make use of
the various ways of integrating findings in their reports.
They report the results of qualitative and quantitative
components separately, or they report the qualitative
and quantitative findings together without considering
how they are related to each other. This indicates that
researchers may be unaware of some of the unique
insights available in mixed methods studies. In our
study, we looked for convergence, divergence and dis-
crepancy in the findings of both methods. This process
is defined as crystallisation.50 Indeed, crystallisation of
results and exploration of definite discrepancies can
lead to further insights. Second, the integration of data
and findings from different components of a mixed
methods study is not always apparent in the articles
emerging from them. This indicates that any unique
insights available from mixed methods studies may not
be disseminated in ways that are attributable to mixed
methods studies.
Lastly, the results of the quantitative longitudinal and
comparative studies and the qualitative studies will be
separately published and will provide pilot data on the
feasibility and impact of a brief transition programme
on patient-reported and parent-reported outcomes in
young people with JIA. The data of this forthcoming
study can be used to design a randomised controlled
trial testing the effectiveness of the programme in a
robust way. Indeed, the effect size obtained in the
present study can be used for power and sample size cal-
culations for future studies. Admittedly, since the
present study is conducted in persons with JIA, the data
are not necessarily generalisable to other patient
populations.
Although we use an innovative embedded experimental
design in the DON’T RETARD project, some limitations
should be addressed. The assessment of the patient’s tran-
sition readiness is no key component of our transition pro-
gramme. Recently, an increasing number of studies
investigated the use of assessment tools such as the
Transition Readiness Assessment Questionnaire
(TRAQ),51 an instrument aiming to evaluate a set of skills
and developmental tasks that should be fulfilled in order
to transfer patients to adult care.
Furthermore, our brief transition programme might
look more as a transfer than a transition programme.
The concept of a transition programme may imply more
transitional care, starting in early adolescence, whereas
this brief intervention starts in the pretransfer period.
Our brief intervention predominantly focuses on coun-
selling and education rather than skills training. Still,
expecting all education needs to be met in the relatively
short programme described is ambitious. Moreover,
regular assessments of education needs should already
be initiated in paediatric care.
In addition, we have to bear in mind that the list of
outcomes we use to assess the clinical impact of our pro-
gramme is non-exhaustive. Additional outcomes such as
self-efficacy or the level of autonomy of patients might
be of interest.52
Finally, since patients who were included in the com-
parison group are already transferred to adult rheuma-
tology, they are older when compared with those in the
intervention group. In addition, transfer of patients in
general occurred somewhat later in the era before our
transition programme. This also contributes to the
higher age of the comparison participants. Hence, a
matching procedure on age is not possible.
CONCLUSION
This methods paper presented the rationale and design
of a study intended to evaluate a transition programme
for young people with JIA as a brief intervention. Here,
we used the MRC framework. The embedded experi-
mental design offers the opportunity to obtain an
overall picture of the clinical impact of the transition
programme on young people with JIA. Furthermore, it
also allows one to get an overall picture of how these
young people experience this programme. This study
protocol is designed to evaluate our brief intervention.
This evaluation enabled us to get more insight into the
active components of our transition programme.
Examination of key clinical and methodological uncer-
tainties in the exploratory trial phase could help
researchers to set up definite randomised controlled
trials and guide long-term implementation.
TRIAL STATUS
The trial started 1 February 2009, and ended on
1 February 2011.
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